 |
160 Products |  |
813 Diseases | | 160 Products |
|
1608 Trials |  |
78055 News |  |
| «12...1112131415161718192021...903904» |
- Tomudex (raltitrexed) / Pfizer, AstraZeneca, Stivarga (regorafenib) / Bayer
Real-world study of anti () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5049;
The combination of anti-PD-1 drugs, regorafenib, and raltitrexed demonstrated promising antitumor efficacy and acceptable safety in patients with metastatic CRC, offering an alternative approach to optimize combination strategies in the management of refractory metastatic colorectal cancer. Clinicopathological characteristics.
- Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Toxicity profile of fruquintinib (Fruq) versus regorafenib (Rego) in refractory metastatic colorectal cancer (mCRC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5047;
Compared to Rego, Fruq showed a more favorable toxicity profile in all TRAEs except in HTN where Fruq had a higher risk. This review emphasizes the need for direct head-to-head comparisons between Fruq and Rego in experimental settings.
- Avastin (bevacizumab) / Roche
A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5035;
Regorafenib (Reg) and TAS-102 have shown promise in mCRC treatment... The results suggest that Fru-based regimens, particularly in combination with ICIs, may offer survival benefits compared to standard regimens, especially in patients without prior Bev use.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
Regorafenib and nivolumab in refractory microsatellite stable, metastatic colorectal cancer and impact of site of dominant disease. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5030;
There was 1 durable CR off all treatment and 1 PR noted in patients with lung dominant disease. Given evidence of exceptional response after exhausting standard therapies, further investigation in patients with lung dominant disease is warranted.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5015;
P3
Limitations include the inability to adjust all covariances, biases due to unobserved covariances, and lacking comparison between reg and TAS102 due to unavailable IPDs. The findings should be validated through future RWS.
- Fruzaqla (fruquintinib) / Takeda
Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_5004;
P3
Furthermore, these analyses are robust with consistent results reported using IPCW and MSM. These findings support fruquintinib as a new treatment option for patients with previously treated mCRC.
- 5-fluorouracil / Generic mfg.
The addition of monoclonal antibodies to chemotherapy in metastatic early-onset colorectal cancer: A comparative effectiveness study using real-world data. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4994;
Our study did not demonstrate survival benefits of initiating first line monoclonal antibodies in stage IV eoCRC, which is likely explained by the fact that survival depends on compliance and subsequent lines of therapy. We did not have access to RAS gene status, an important predictor of treatment response.
- Lonsurf (trifluridine/tipiracil) / Otsuka
The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4992;
We did not have access to RAS gene status, an important predictor of treatment response. In the previous studies, the overall survival would increase by 6-8 months with trifluridine
- Fruzaqla (fruquintinib) / Takeda
Cardiovascular toxicity of fruquintinib in patients with colorectal and other cancers: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4977;
Our study found that Fruquintinib is associated with significant cardiovascular risks, with hypertension being the most common adverse event, while thromboembolism did not reach statistical significance. Therefore, close monitoring for treatment-related cardiovascular events should be considered in these patients.
- Fruzaqla (fruquintinib) / Takeda
Real-world experience of fruquintinib in patients with metastatic colorectal cancer: A single-center retrospective study in the United States. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4967;
The safety profile was consistent with the FRESCO-2 study, though patients with ECOG > 1 experienced greater toxicity. Efficacy appeared lower in those previously treated with regorafenib.
- Outcomes with KRAS G12C inhibitors in metastatic colorectal cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4965;
KRAS G12C inhibitors demonstrated promising efficacy in metastatic KRAS G12C mutated CRC with an acceptable toxicity profile. However, large studies with randomization are needed to consolidate these findings.
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
The prognostic value of acneiform rash grade in metastatic colorectal cancer patients treated with EGFR inhibitors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4957;
Specifically, patients with higher-grade rashes had an approximately 40% reduction in the risk of both progression and death for each increase in rash grade. These findings suggest that rash grade may serve as a prognostic indicator of treatment outcomes, offering insight into patient management strategies and guiding clinical decision-making in EGFRi therapy.
- Stivarga (regorafenib) / Bayer
Comparison of the efficacy and safety of regorafenib monotherapy and regorafenib combination therapy in the third-line treatment of metastatic colorectal cancer: A real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4954;
Regorafenib alone or in combination with TAS-102 or anti-PD-1 is safe and feasible for third-line treatment of mCRC. Additional prospective large-scale studies are required to explore combination therapy.
- Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4921;
Fruquintinib sequenced after TAS-102 +/- bev may confer an OS advantage in the treatment of mCRC. However, prospective studies evaluating sequencing strategies representative of standard prescribing patterns are still needed to firmly establish optimal sequencing of fruquintinib, regorafenib, and TAS-102-based therapy.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
Sex differences in toxicities among patients receiving regorafenib or trifluridine/tipiracil for refractory metastatic colorectal cancer: A subgroup analysis from the multicenter retrospective ReTrITA study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4889;
In order to enhance comprehension of toxicities associated with sex in the future, the analysis of toxicity events could represent a valuable instrument to facilitate the collection of extensive datasets, thereby enabling a more in-depth comparison of male and female patients. Furthermore, using patient-reported outcomes may help us gain a better knowledge of the impact of anticancer treatment based on sex and gender.
- Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
Navigating third-line therapies: A comprehensive review of regorafenib versus fruquintinib with placebo comparator for metastatic colorectal cancer () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4878;
Regorafenib and Fruquintinib offer similar clinical benefits in refractory mCRC, but Fruquintinib may have a more favorable toxicity profile, particularly for all-grade adverse events. These findings suggest that Fruquintinib could be a preferred option based on tolerability, though both agents remain essential therapeutic options in advanced mCRC.
- Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4866;
In 20 studies, EGFRi rechallenge was given only to patients previously progressing on 5-fluoropyrimidine, oxaliplatin or irinotecan...The pooled ORR was 15% (95% CI, 9%-24%) which is numerically higher than that achieved by FDA-approved third-line agents (trifluridine/tipiracil plus bevacizumab 6.1%, fruquintinib 2%, and regorafenib 1.5%)... EGFRi rechallenge is associated with a significantly longer PFS, numerically longer OS and clinically meaningful ORR as compared with EGFRi-free systemic therapy in patients with heavily-pretreated mCRC, particularly for patients with pre-rechallenge RAS/RAF-wild type mCRC.
- Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
Trifluridine tipiracil with bevacizumab in refractory metastatic colorectal cancer with a convenient two weekly schedule: An Indian single center experience. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4865;
Two weekly regimen was better tolerated and also convenient in this heavily pre-treated population. Considering the significant dose reductions due to low counts, we would suggest studying this two weekly combination regimen at a lower starting dose of FTD-TPI in a larger study in India.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
CDK inhibitors and radiation therapy in breast cancer: Hematologic toxicity and survival implications. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4804;
In conclusion, our study shows that administration concurrent or sequential RT and CDK4/6 inhibitors together prolonged disease-free survival and overall survival, but also increased hematologic toxicities. Since these toxicities are manageable, we frequently use RT with CDK4/6i in our clinical practice.
- ABP1019A / AB Pharma
A phase I clinical trial of ABP1019A monotherapy in patients with advanced malignant solid tumors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4786;
P1
Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1019A in phase I dose escalation study showed that this monotherapy was well tolerated, and had preliminary anti-tumor efficacy on advanced pancreatic cancer, glioma, lung and thyroid cancer, etc. A phase II exploratory study is ongoing to further verify the safety and anti-tumor efficacy of ABP1019A on 8 types of tumors including glioma, pancreatic cancer, osteosarcoma, cholangiocarcinoma, SCLC, colorectal cancer, esophageal cancer, and gastric cancer.
- ABP-1011T / AB Pharma
A phase IIa clinical trial of ABP1011T monotherapy in patients with advanced malignant solid tumors. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4726;
P1/2
Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1011T in Phase IIa exploratory study showed that ABP1011T was well tolerated, and its mono-therapy showed varying degrees of tumor shrinkage in advanced sarcoma , SCLC, EC, BC, and cervical cancer that had been treated with Anlotinib and PD-1, etc. A phase IIb study of ABP1011T will be conducted to further validate the safety, tolerability and efficacy in advanced malignant solid tumors.
- Iclusig (ponatinib) / Takeda, Blincyto (blinatumomab) / Astellas, Amgen
Efficacy and safety of combination therapy of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4723;
The combination of ponatinib and blinatumomab shows promising results in achieving event-free survival, overall survival, and complete molecular response in Ph+ ALL patients, with a manageable safety profile (16% adverse effects) at 24 months. However, well-defined studies with larger sample sizes are needed for definitive conclusions.
- Imdelltra (tarlatamab-dlle) / Amgen, Rybrevant (amivantamab-vmjw) / J&J, Lazcluze (lazertinib) / J&J
Thrombotic events and mortality associated with bispecific antibodies in lung cancer: A systematic review. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4708;
However, well-defined studies with larger sample sizes are needed for definitive conclusions. Amivantamab (EGFR + MET) and tarlatamab (Delta-like ligand 3 x CD3) were used in 80% and 20% of cases for advanced non
- Meta-analysis of the cardiovascular adverse effects of bispecific antibodies in malignant hematology therapies. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4614;
This meta-analysis has identified tachycardia, cardiac arrhythmias, and hypotension as the most significant cardiac adverse events in a pooled analysis of multiple BsAbs. Practicing oncologists, cardiologists, and pharmacists need not only to be aware of these potential toxicities, but also to establish strategies for cardiac monitoring, prevention and management in order to provide quality care to cancer patients.
- ifebemtinib (IN10018) / InxMed, Opdivo (nivolumab) / Ono Pharma, BMS, Lumakras (sotorasib) / Amgen
Targeting focal adhesion kinase to mitigate hepatotoxicity induced by PD-1 inhibition with or without KRAS G12C suppression. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4597;
Practicing oncologists, cardiologists, and pharmacists need not only to be aware of these potential toxicities, but also to establish strategies for cardiac monitoring, prevention and management in order to provide quality care to cancer patients. FAK inhibition with Ifebe effectively reduces liver toxicity associated with KRAS G12C inhibition and PD-1 antibody therapy, underscoring the need for further clinical investigation.
- Ibrance (palbociclib) / Pfizer, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Tecentriq (atezolizumab) / Roche
Outcomes and prognostic factors in breast cancer patients with leptomeningeal metastasis: Insights from a retrospective analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4573;
Invasive lobular CA and TNBCA were associated with shorter survival post-LM. Multimodal treatment showed statistically nonsignificant improved survival providing a benchmark for future studies.
- Ibrance (palbociclib) / Pfizer
Health economic impact of active e-health support in patients with advanced and metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4515;
P4
In addition to extending the interval of high quality of life and SAE-free survival, AeHS by Cankado PRO-React or similar applications could provide significant intangible benefits from societal and patient perspectives. Future trials designed to detect improvements in medication adherence or time to therapy discontinuation could demonstrate further positive impacts of AeHS.
- Lumakras (sotorasib) / Amgen
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4377;
These findings position krasID as a next-generation biomarker for identifying KRASi responders, predicting treatment duration, and guiding personalized follow-on therapies for KRAS-mutated cancers. Performance of time on sotorasib classifier
- Blincyto (blinatumomab) / Astellas, Amgen, Vitrakvi (larotrectinib) / Bayer
Understanding access to novel high-cost therapies across Canada: A survey of pediatric oncology providers. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4344;
The direct costs of these therapies must be addressed to make them less prohibitive for families; however, strategies must also be developed to mitigate psychosocial and economic impacts of travelling to obtain therapies. Universal funding of these therapies, and simplified access to proton therapy centres, including the development of Canadian proton therapy facilities, would increase equitable access, ultimately improving outcomes for children with cancer.
- Ibrance (palbociclib) / Pfizer
Palbociclib plus endocrine therapy or GnRH analogs versus capecitabine or placebo for HR+/HER2- metastatic breast cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4187;
Future research directions should explore the long-term efficacy and safety of palbociclib plus ET for the treatment of metastatic breast cancer in diverse clinical settings. This review offers insights for clinical decision-making within the dynamic and advancing field of breast cancer treatment.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Factors impacting treatment with a CDK4/6i in first line metastatic HR+/HER2- breast cancer patients. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4159;
Background: The inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i), abemaciclib, palbociclib and ribociclib, are indicated for the treatment of metastatic breast cancer (mBC) patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) disease. Pts with HR+/HER2- mBC who initiated LOT 1 therapy were more likely to receive a CDK4/6i if they were between the age of 46 and 85, had metastasis to the bone, had a better performance status (ECOG 5 HR+/HER2- mBC pts who initiated LOT 1.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Prognostic value of estrogen receptor (ER) and progesterone receptor (PR) expression levels in de novo and recurrent HR+/HER2- metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): Real-world evidence. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4141;
These differences may be due to intrinsic or acquired resistance and support the need for repeat biopsy for rMBC. RN, not reached; dCDKi, PFS2, OS are in months
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Assessing venous thromboembolism risk in HR+/HER2- breast cancer patients receiving CDK4/6 inhibitors: Insights from real-world data in the Middle East. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4124;
Future risk assessment tools needed to be applied in breast cancer patients receiving CDK4/6 inhibitors and risk of developing thrombosis. Incidence of ThrombosisIQR = Interquartile range
- Ibrance (palbociclib) / Pfizer
Prognostic profiling of hormone receptor () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4102;
The SCA developed in this analysis confirmed findings from the PACE prospective trial and highlighted a differential prognostic impact of ctDNA features across treatment subgroups. These results provide valuable insights for personalized treatment algorithms and could guide therapeutic decisions and future clinical trial design.
- Prolia (denosumab) / Amgen
Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: A real-world cohort study on skeletal events and safety. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4095;
Early denosumab initiation after bone-metastasis diagnosis may lead to better clinical outcomes. These findings suggest that patients who receive denosumab promptly as the primary treatment for bone metastases may have greater benefits.
- Clinical investigators' (CIs) practice patterns for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) harboring PI3K/AKT/PTEN pathway abnormalities (PAPm). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4093;
Future work is needed to explore how other factors (eg, age, comorbidities, HER2-low status) and rapidly emerging clinical trial findings (eg, EMBER-3) affect decision-making. A = anastrozole; IPF = inavolisib + palbociclib + fulvestrant; F = fulvestrant; AI = aromatase inhibitor; C = capivasertib; Alp = alpelisib; E = elacestrant
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical factors affecting clinical investigators' (CIs) selection of CDK4/6 inhibitors (CDKis) for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC). () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4092;
It would be interesting and relevant to explore whether matching approaches are being undertaken in community oncology practice. R = ribociclib; AI = aromatase inhibitor; P = palbociclib; A = abemaciclib; MI = myocardial infarction
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Efficacy of CDK4/6 inhibitors post-chemotherapy in HR+ HER2- metastatic breast cancer patients: Real-world study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4079;
The retrospective nature of this study introduces potential biases, including patient selection and inherently more aggressive disease biology that may have influenced the decision to use chemotherapy in the first line. Further analyses are necessary to clarify these findings.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Tolerance to CD4/6 inhibitor therapy as first line therapy among ER+ patients with metastatic breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4062;
First-line therapies included palbociclib (54.9%), ribociclib (10.9%), and abemaciclib (9.7%). Racial disparities in treatment patterns and outcomes, including shorter therapy durations for Black patients, underscore the need for personalized strategies and equitable care in metastatic breast cancer.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Real-world data on the effectiveness and toxicity of CDK 4/6 inhibitors combined with hormonal therapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer in first- and second-line treatments within the Costa Rican health care system. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4058;
The data suggest that if palbociclib is used, it should ideally be initiated in the first-line setting to optimize clinical benefit. Continued research and regional data are crucial for refining treatment strategies.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase ? trial. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4057;
P2
Among these patients, 21 (70.0%) received abemaciclib, and 10 (33.3%) received palbociclib and ribociclib. Our results indicated that dalpiciclib plus fulvestrant and pyrotinib achieves promising efficacy and safety in in HR+, HER2-low advanced BC patients following CDK4/6i and AI treatment.
- Prolia (denosumab) / Amgen
Diagnostic value of PET-CT for early detection of MRONJ in breast cancer patients. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4056;
These results are highly relevant for clinical practice as many patients receive regular PET/CTs and this provides the opportunity to detect MRONJ with a lead time that allows for early intervention. Presence of jaw lesion *These values were adjusted assuming disease prevalence of 11.6% according to Brunner et al JCO August 2024, https://doi.org/10.1200/JCO.24.00171
- Ibrance (palbociclib) / Pfizer
A retrospective, multicentric, observational, real-world evidence (RWE) study on cost impact, efficacy, and safety of generic palbociclib in HR+ve, HER2-ve metastatic breast cancer: An Indian perspective. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4054;
It improves progression-free survival, response rates, and affordability. The substantial cost reduction significantly alleviates the financial burden on patients, improving treatment accessibility.
- Ibrance (palbociclib) / Pfizer
Real world evidence on effectiveness of palbociclib in Indian patients with breast cancer: A single centre, investigator-initiated, retrospective study. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4041;
BC. Baseline demographics
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Efficacy and safety of CDK4/6 inhibitors in HER2-positive breast cancer: A systematic review and meta-analysis. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4037;
However, they are not yet standard treatment. Further studies are needed to confirm these findings and establish optimal treatment protocols.
- Ibrance (palbociclib) / Pfizer
Real-world data analysis of safety and efficacy of palbociclib in HR positive, HER-2 negative MBC patients, at tertiary care hospital at Middle East, Saudi Arabia. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4030;
Neutropenia was the most frequent adverse event, requiring dose adjustments. These findings emphasize the need for proactive monitoring and management of neutropenia in this population.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Outcomes with CDK4/6 inhibitor in metastatic hormone receptor () - Apr 23, 2025 - Abstract #ASCO2025ASCO_4028;
The OS and PFS reported are similar to real-world studies even though the complete remission rates and adverse events were lower than western data which could be attributed to difference in tumor biology. There is no difference in survival with use of CDKi in first line versus subsequent lines.
- Ibrance (palbociclib) / Pfizer, Bavencio (avelumab) / EMD Serono
Spatial transcriptomic analysis of the ImmunoADAPT trial: Neoadjuvant endocrine therapy combined with palbociclib and avelumab in early-stage ER-positive breast cancer. () - Apr 23, 2025 - Abstract #ASCO2025ASCO_3989;
P2
Our results align with preclinical data showing that CDK4/6 inhibitors can upregulate adaptive immune cascades in the tumor microenvironment, including Ag presentation, T cell recruitment and activation. In our trial, the patients who responded to PETA were the ones who achieved an immune upregulation at C2D1 after treatment with palbociblib+ET.
- Stivarga (regorafenib) / Bayer
Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study. (S100bc) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3825;
P1
The efficacy of the addition of regorafenib to standard multimodal treatment in newly diagnosed patients with metastatic Ewing sarcoma will be tested in the Inter-Ewing-1 trial developed by the Euro Ewing Consortium (planned initiation in Q3 2025). Recruitment to the Rego-Inter-Ewing-1 continues at DL1 (maximum 24 patients), until Inter-Ewing-1 initiates.
- ZL-1310 / ZAI Lab
ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. (Hall A - Posters and Exhibits; Poster Bd #: 356) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3657;
P1
ZL-1310 demonstrated a tolerable safety profile and promising antitumor activity in r/r ES-SCLC, including pts with brain metastases, pt with prior tarlatamab, and in the setting of low DLL3 expression. Updated data, including patients in the randomized Part 2 dose optimization, will be presented.